In a recent study, researchers looked at two randomized comparative trials evaluating COVID-19 treatments and outlined the problematic gaps created by the use of the Kaplan-Meier method and hazard ratio.
Firma’s Dr. D.J. Tang shares in an Outsourcing-Pharma article why RWD can be useful in drug research and development.
Firma Clinical recently commenced a Scientific Advisory Board for its clinical services, including biometrics/data.
In Outsourcing-Pharma, Melissa Nezos, explains how the pandemic increased the need to bring the study to the patient.
Firma’s Melissa Nezos shares in an Applied Clinical Trials article the important role of home visits in hybrid and decentralized/virtual clinical trials.
Firma Clinical has joined DTRA, an alliance of life sciences and healthcare organizations seeking to accelerate the broad adoption of patient-focused, decentralized clinical trials and research.
